Biblio Discovery — Demo Discovery Service

10 hasil untuk "Xiuning Le"

Menampilkan 1–10 · 0,48 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy

    Sonia A. Patel; Monique B. Nilsson; Xiuning Le dkk.

    Clinical Cancer Research · 2022 · Inggris · OpenAlex Scopus

    Angiogenesis, the sprouting of new blood vessels from existing vessels, is one of six known mechanisms employed by solid tumors to recruit blood vessels necessary for their initiation, growth, and metastatic spread. The vascular network within the tumor facilitates the transport of nutrients…

  2. Artikel Jurnal Teks lengkap

    AI in drug discovery and its clinical relevance

    Rizwan Qureshi; Muhammad Faisal Irfan; Taimoor Muzaffar Gondal dkk.

    Heliyon · 2023 · Inggris · OpenAlex Scopus

    The COVID-19 pandemic has emphasized the need for novel drug discovery process. However, the journey from conceptualizing a drug to its eventual implementation in clinical settings is a long, complex, and expensive process, with many potential points of failure. Over the past decade, a vast growth…

  3. Artikel Jurnal

    Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC

    Xiuning Le; Monique B. Nilsson; Jonathan Wade Goldman dkk.

    Journal of Thoracic Oncology · 2020 · Inggris · OpenAlex Scopus

    The VEGF pathway has been recognized as a key mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting VEGF and VEGF receptors have been developed and approved for use in NSCLCs. Preclinical studies have found that the VEGF and EGFR pathways share common downstream…

  4. Artikel Jurnal Teks lengkap

    Structure-based classification predicts drug response in EGFR-mutant NSCLC

    Jacqulyne Ponville Robichaux; Xiuning Le; R. S. K. Vijayan dkk.

    Nature · 2021 · Inggris · OpenAlex Scopus

    Abstract Epidermal growth factor receptor ( EGFR ) mutations typically occur in exons 18–21 and are established driver mutations in non-small cell lung cancer (NSCLC) 1–3 . Targeted therapies are approved for patients with ‘classical’ mutations and a small number of other mutations 4–6 . However…

  5. Artikel Jurnal Teks lengkap

    Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

    Paul K. Paik; Enriqueta Felip; Rémi Veillon dkk.

    New England Journal of Medicine · 2020 · Inggris · OpenAlex Scopus

    BACKGROUND: occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population. METHODS: exon 14 skipping mutation was detected on liquid biopsy or tissue biopsy. RESULTS: As of…

  6. Artikel Jurnal Teks lengkap

    Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

    Marcelo Vailati Negrao; Ferdinandos Skoulidis; Meagan Montesion dkk.

    Journal for ImmunoTherapy of Cancer · 2021 · Inggris · OpenAlex Scopus

    Background Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has been attributed to low tumor mutation burden (TMB) and/or PD-L1 levels. We investigated oncogene-specific differences in…